What is Novo really up against?
05/02/26 -"The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they might not make profits at anything less ..."
Pages
74
Language
English
Published on
05/02/26
You may also be interested by these reports :
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...
05/02/26
The Q4 25 performance exceeded expectations, ensuring that GSK delivered on the higher end of the 2025 guidance. HIV, Respiratory, Immunology and ...
04/02/26
The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was ...
04/02/26
Even though the Q4 performance ensured that Novo delivered on the lowered 2025 expectations, the markets seem frustrated with the 2026 outlook, ...